San Francisco, 14
January, Hemoglobinopathies Market Size & Forecast By Type (Alpha
Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases), By
Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant,
Hydroxyurea), By Diagnosis (Blood Testing, Genetic Testing, Prenatal Genetic
Testing, Pre-implantation Genetic Diagnosis, Hemoglobin Electrophoresis) And
Trend Analysis From 2012 To 2022
Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022
according to a new report by Grand View Research Inc. Rising prevalence of
hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is
estimated to be the high impact rendering drivers of the market. According to
the WHO, hemoglobin disorders are endemic in over 60% of 229 countries
affecting over 70% of births. It is also reported that minimum 5% of the world
population are carriers of significant variation.
Prevalence of hemoglobinopathies
is high in low-income countries such as Sub Saharan region and South East Asia.
85% of the affected population in the U.S. and Europe has ancestral base in
these regions.
Governments are collaborating
with local institutes to undertake awareness programs for curbing the effect of
hemoglobinopathies-related mortality rate. For instance, Thalassemia Data
Collection Project and Registry and Surveillance System for Hemoglobinopathies
(RuSH) projects were started in 2010 by the Centers for Disease Control and
Prevention (CDC).
Low level of hygiene,
insufficient healthcare infrastructure, and lesser awareness levels are some
key factors attributing to increase in base of target population in low-income
regions such as South East Asia, Mediterranean basin, and Africa.
Access Full
Research Report On Hemoglobinopathies Market Analysis:
Further key findings from the study suggest:
·
The market for Sickle Cell
Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million
in 2014. Rising prevalence of hemoglobinopathies and presence of strong product
pipeline for sickle cell anemia such as HQK-1001 and Luspatercept are growth
promoting factors of this market.
·
Genetic testing for diagnosis
of sickle cell disorders is expected to witness lucrative growth over the
forecast period. It is estimated to grow at a CAGR of around 7.0%. Increasing
awareness levels among people coupled with government programs such as the
National Sickle Cell Disease Control Program conducted by the WHO in Africa are
anticipated to enhance the usage rates for diagnostic tests pertaining to SCD.
·
Hydroxyurea was one of the
dominating segments of the SCD therapy market owing to the presence of the
FDA-approved drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD.
Thalassemia market holds an extensive product portfolio in pipeline and their
expected commercialization is anticipated to drive market growth. For instance,
The Ellis Lab is developing a gene therapy for SCD in collaboration with Dr.
Victor Garcia
·
Blood tests including cell
blood count and iron studies are the widely used techniques for diagnosis of
thalassemia. On the other hand, pre-implant genetic testing is estimated to
grow at lucrative growth rate over 8.5% in the next six years owing to rising
base of health conscious population and increasing healthcare expenditure.
·
The market for blood
transfusion was the largest with revenues valued at over USD 1,408.0 million in
therapeutic segment owing to, high acceptance level of this treatment option
and significant success rate. It is estimated that around 85% of infants below
five years suffering from thalassemia die due to insufficient blood
transfusion.
·
North America dominated the
overall hemoglobinopathies market in terms of revenue in 2014 at over USD
1,212.0 million. Growing prevalence of blood disorders, favorable government
programs, and high level of awareness among healthcare professionals and
patients for hemoglobinopathies-related genetic testing are factors attributing
to the major share of this market.
·
Asia Pacific market is expected
to witness lucrative growth over the forecast period with a CAGR of over 10%
owing to the presence of high unmet clinical needs, improving healthcare
infrastructure, and rising economic levels. Moreover, introduction of low-cost
diagnostic alternatives will enhance adoption rates for hemoglobinopathies
diagnostics market.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
hemoglobinopathies market on the basis of type, diagnostics, and therapeutics:
Global Hemoglobinopathies
Therapy Outlook (Revenue, USD Million), 2012 – 2022
·
Thalassemia
o
Alpha thalassemia
o
Beta thalassemia
·
Sickle cell disease
·
Hemoglobin variants diseases
Global Hemoglobinopathies
Diagnosis Outlook (Revenue, USD Million), 2012 – 2022
·
Thalassemia
o
Alpha thalassemia
o
Beta thalassemia
·
Sickle cell disease
·
Hemoglobin variants diseases
Hemoglobinopathies Regional
Outlook (Revenue, USD Million), 2012 – 2022
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
MEA
o
South Africa
Access Full Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/